Similar articles for PMID: 30969331

Year	Number of Results
1975	1
1976	3
1980	1
1985	1
1986	2
1989	1
1993	1
1997	1
1998	1
1999	5
2000	3
2001	6
2002	6
2003	6
2004	3
2005	6
2006	5
2007	5
2008	4
2010	3
2012	3
2013	1
2014	4
2015	5
2016	5
2017	2
2019	3
2020	2
2021	4
2022	5
2024	0

1

Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical?

Lawrence RE, Appelbaum PS, Lieberman JA. Lawrence RE, et al. JAMA Psychiatry. 2019 Jul 1;76(7):673-674. doi: 10.1001/jamapsychiatry.2019.0275. JAMA Psychiatry. 2019. PMID: 30969331 No abstract available.

2

Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia.

Emsley R, Fleischhacker WW, Galderisi S, Halpern LJ, McEvoy JP, Schooler NR. Emsley R, et al. BMJ. 2016 Sep 9;354:i4728. doi: 10.1136/bmj.i4728. BMJ. 2016. PMID: 27613560 No abstract available.

3

The use of placebo in schizophrenia relapse prevention studies: scientific or ethical debate?

Ćurković M, Borovečki A. Ćurković M, et al. Acta Psychiatr Scand. 2019 Oct;140(4):386-387. doi: 10.1111/acps.13085. Acta Psychiatr Scand. 2019. PMID: 31407323 No abstract available.

4

A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise.

Lawrence RE, Appelbaum PS, Lieberman JA. Lawrence RE, et al. Schizophr Res. 2021 Mar;229:122-131. doi: 10.1016/j.schres.2020.11.022. Epub 2020 Nov 22. Schizophr Res. 2021. PMID: 33234427 Review.

5

Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?

Emsley R, Fleischhacker WW. Emsley R, et al. Schizophr Res. 2013 Nov;150(2-3):427-33. doi: 10.1016/j.schres.2013.09.008. Epub 2013 Oct 2. Schizophr Res. 2013. PMID: 24094881 Review.

6

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Leucht S, et al. Am J Psychiatry. 2003 Jul;160(7):1209-22. doi: 10.1176/appi.ajp.160.7.1209. Am J Psychiatry. 2003. PMID: 12832232 Review.

7

Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

Weijer C. Weijer C. Schizophr Res. 1999 Feb 15;35(3):211-8; discussion 227-36. doi: 10.1016/s0920-9964(98)00127-3. Schizophr Res. 1999. PMID: 10093865

8

Analysis of antipsychotic dose reduction.

Uchida H, Suzuki T, Takeuchi H, Mamo DC. Uchida H, et al. Am J Psychiatry. 2010 Aug;167(8):994; author reply 994-5. doi: 10.1176/appi.ajp.2010.10030409. Am J Psychiatry. 2010. PMID: 20693469 No abstract available.

9

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Berwaerts J, et al. JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241. JAMA Psychiatry. 2015. PMID: 25820612 Clinical Trial.

10

Relapse prevention in schizophrenia.

Jauhar S, Laws K, Fusar-Poli P, McKenna P. Jauhar S, et al. Lancet Psychiatry. 2022 Apr;9(4):e13. doi: 10.1016/S2215-0366(21)00501-0. Lancet Psychiatry. 2022. PMID: 35305747 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year